Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
There was a significant increase in out-of-pocket costs for all 4 cancer types studied.
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.
In 2019, the FDA granted accelerated approval to Tecentriq, a PD-L1 blocking antibody, for unresectable locally advanced or metastatic TNBC.
The current scientific evidence may not be generalizable to underrepresented groups.
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Prior data suggested the incidence may be as high as 16%.
About 31% of the articles analyzed contained information classified as harmful.
Surgery was an independent predictor of overall survival.